Polina Greenberg

Rehovot, M, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome.

Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome.

Journal: Immunity

Published: August 12, 2025

Lymphodepleting chemotherapy potentiates neoantigen-directed T cell therapy by enhancing antigen presentation.

Lymphodepleting chemotherapy potentiates neoantigen-directed T cell therapy by enhancing antigen presentation.

Journal: Cell reports. Medicine

Published: March 03, 2025

HLA export by melanoma cells decoys cytotoxic T cells to promote immune evasion.

HLA export by melanoma cells decoys cytotoxic T cells to promote immune evasion.

Journal: Cell

Published: January 08, 2025

Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer.

Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer.

Journal: Cancer discovery

Published: September 02, 2024

Translation dysregulation in cancer as a source for targetable antigens.

Translation dysregulation in cancer as a source for targetable antigens.

Journal: Cancer cell

Published: June 19, 2024

Identification of presented SARS-CoV-2 HLA class I and HLA class II peptides using HLA peptidomics.

Identification of presented SARS-CoV-2 HLA class I and HLA class II peptides using HLA peptidomics.

Journal: Cell reports

Published: November 03, 2020

Identification of bacteria-derived HLA-bound peptides in melanoma.

Identification of bacteria-derived HLA-bound peptides in melanoma.

Journal: Nature

Published: November 04, 2019

Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma.

Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma.

Journal: The Journal of clinical investigation

Published: April 10, 2019

Correction: CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma.

Correction: CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma.

Journal: Oncotarget

Published: March 14, 2019

Author Correction: RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells.

Author Correction: RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells.

Journal: Scientific reports

Published: March 10, 2019

Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma.

Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma.

Journal: Nature communications

Published: October 10, 2018

CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma.

CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma.

Journal: Oncotarget

Published: March 07, 2018

Showing 1-12 of 14

Last Updated: 09/26/2026